Literature DB >> 12010224

Risk factors for developing renal stones in inflammatory bowel disease.

N McConnell1, S Campbell, I Gillanders, H Rolton, B Danesh.   

Abstract

OBJECTIVE: To correlate renal calculi and other clinical factors with urinary biochemical analytes in patients with inflammatory bowel disease, and to investigate the relative importance of hyperoxaluria (associated with fat malabsorption) or reduced stone inhibitors in the development of calculi in these patients. PATIENTS, SUBJECTS AND METHODS: Samples were obtained from 25 patients with Crohn's disease (CD), 15 with ulcerative colitis (UC) and 17 normal subjects (controls). Evidence for the presence of renal calculi was obtained from plain films, ultrasonography or intravenous urography. Urine oxalate and citrate were analysed using commercial enzymatic assays; magnesium was measured using atomic absorption and other analytes assayed using standard methods on automated analysers.
RESULTS: Renal calculi were found in two patients with CD and in none with UC. Hyperoxaluria was present in 36% of patients with CD but was absent in those with UC. Analysis of covariance showed an association between low urinary citrate/creatinine ratio and renal stones (P=0.02), and between a combined urinary citrate and magnesium deficit relative to calcium, as expressed in the CMC index ((citratexmagnesium)/calcium), and renal stones (P=0.017). Changes in urinary calcium, oxalate, urate, magnesium or the calcium oxalate index were not associated with the presence of stones. There was no independent relationship between any clinical factor and the presence of stones.
CONCLUSION: Lower urinary concentrations of magnesium and citrate (stone inhibitors), relative to calcium (stone promoter; the CMC index) may be more important in lithogenesis in inflammatory bowel disease than is hyperoxaluria. In patients with a functioning colon, a low CMC index may predict likely stone-formers; this requires a prospective evaluation. Avoiding low urinary levels of magnesium and citrate may aid in preventing and treating renal calculi.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010224     DOI: 10.1046/j.1464-410x.2002.02739.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

Review 1.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

2.  Metabolic stress response patterns in urinary compositions of idiopathic calcium oxalate stone formers, patients with chronic bowel diseases and controls.

Authors:  Wolfgang Berg; Sabine Gayde; Christine Uhlemann; Norbert Laube
Journal:  Urol Res       Date:  2010-05-04

3.  Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI).

Authors:  Sasan Fallahi; Ahmad Reza Jamshidi; Farhad Gharibdoost; Mahdi I Mahmoud; Pedram Paragomi; Mohammad Hossein Nicknam; Elham Farhadi; Mostafa Qorbani
Journal:  Caspian J Intern Med       Date:  2012

4.  Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.

Authors:  Laurence Richard Solomon; Andrew Christopher Nixon; Leanne Ogden; Beena Nair
Journal:  BMJ Case Rep       Date:  2017-11-12

5.  Stress-stones-stress-recurrent stones: a self-propagating cycle? Difficulties in solving this dichotomy.

Authors:  Montserrat Arzoz-Fabregas; Josep Roca-Antonio; Luis Ibarz-Servio; Dalielah Jappie-Mahomed; Allen Rodgers
Journal:  Urolithiasis       Date:  2017-03-21       Impact factor: 3.436

6.  Experimental determination of multiple thermodynamic and kinetic risk factors for nephrolithiasis in the urine of healthy controls and calcium oxalate stone formers: does a universal discriminator exist?

Authors:  A L Rodgers; D Webber; B Hibberd
Journal:  Urolithiasis       Date:  2015-07-22       Impact factor: 3.436

Review 7.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

Review 8.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

Review 9.  Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Authors:  Guru Trikudanathan; Preethi G K Venkatesh; Udayakumar Navaneethan
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

10.  Prevalence of Renal Stones Among Patients With Inflammatory Bowel Disease in Saudi Arabia.

Authors:  Mahmoud Mosli; Abdulrahman M Alzahrani; Rafeef A Bahafzalla; Tala A Gazzaz; Rahaf M Slaghour; Ghidah Z Altabsh; Sarah B Aljadani; Razan N Alturkestani; Sondos S Hussein; Abdullah Kashgary; Omar I Saadah
Journal:  Cureus       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.